Drug Use-Results Survey of PIASKY for Injection 340mg (All-Patient Surveillance) -Paroxysmal nocturnal hemoglobinuria-

Drug Use-Results Survey of PIASKY for Injection 340mg (All-Patient Surveillance) -Paroxysmal nocturnal hemoglobinuria- - Drug Use-Results Survey of PIASKY for Injection 340mg (All-Patient Surveillance) -Paroxysmal nocturnal hemoglobinuria-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054325

Enrollment

100

Registered

2024-05-07

Start date

2024-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal nocturnal hemoglobinuria

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients eligible for enrollment: all patients expected to receive the drug during the enrollment period Patients eligible for case report form (CRF) collection: all patients eligible for enrollment who receive the drug Data will be collected retrospectively from patients who receive the drug before conclusion of the agreement for this surveillance study, and CRFs will be collected for all patients who receive the drug.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Occurrence of adverse drug reactions Changes in LDH and CH50 from baseline	—

Countries

Japan

Contacts

Public ContactAyako Murayama

Chugai Pharmaceutical Co. Ltd Safety Science 2 Department

murayamaayk@chugai-pharm.co.jp03-3281-6611

Outcome results